Geode Capital Management LLC Has $17.91 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Geode Capital Management LLC increased its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 3.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,234,805 shares of the company’s stock after buying an additional 38,927 shares during the quarter. Geode Capital Management LLC owned 1.27% of ARS Pharmaceuticals worth $17,909,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in ARS Pharmaceuticals by 99.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock valued at $1,185,000 after buying an additional 69,394 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter valued at $87,000. Rhumbline Advisers increased its stake in shares of ARS Pharmaceuticals by 78.0% in the second quarter. Rhumbline Advisers now owns 65,942 shares of the company’s stock worth $561,000 after acquiring an additional 28,888 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of ARS Pharmaceuticals during the second quarter worth $231,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ARS Pharmaceuticals

In other news, major shareholder James E. Flynn sold 528,456 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the sale, the insider now owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. This trade represents a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the transaction, the insider now owns 1,098,499 shares of the company’s stock, valued at approximately $12,819,483.33. The trade was a 8.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,258,058 shares of company stock worth $19,369,686. Company insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Trading Down 3.2 %

NASDAQ:SPRY opened at $10.79 on Friday. The firm has a market capitalization of $1.05 billion, a PE ratio of -21.16 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 1 year low of $5.19 and a 1 year high of $18.51. The firm’s fifty day simple moving average is $13.91 and its 200 day simple moving average is $12.53.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Leerink Partners upped their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $24.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.